EXAM:
PET-CT SKULL BASE TO MID-THIGH
CLINICAL HISTORY:
Metastatic prostate cancer, rising PSA
TECHNIQUE:
PET/CT skull base to thigh-subsequent treatment strategy
F18 PYL dose: 10.00 millicuries
Injection site: L AC
Time of injection: 17:00
Time of emission scan: 18:06
Oral Contrast: No
Intravenous Contrast: None
Intravenous Lasix: None
The low-mAs CT Protocol used for this PET/CT study is designed for attenuation correction
and anatomic localization of PET abnormalities.
The standard uptake values (SUV) reported below are maximum values within a region of interest,
expressed in gm/ml.
COMPARISON:
02/02/2024
CORRELATION:
None
FINDINGS:
Mean liver SUV: 5.9, previously 5.2
Mean blood pool SUV: 1.7, previously 1.6
Mean right parotid gland SUV: 18.3, previously 24.7
HEAD/FACE: Physiologic PSMA uptake is seen in the lacrimal and salivary glands.
NECK: Physiologic PSMA uptake is seen in neck muscles.
CERVICAL NODES: No abnormal PSMA uptake.
MEDIASTINUM/HEART/GREAT VESSELS: Physiologic PSMA uptake in the mediastinal blood pool. Coronary artery calcifications.
LUNGS: Small azygous lobe. No abnormal PSMA uptake.
*New non PSMA avid 0.3 cm solid pulmonary nodule in the right upper lobe (image 122)
*Newly appreciated non PSMA avid subpleural ground-glass opacity in right lower lobe (image 147)
Biapical scarring. Unchanged bandlike opacity in the left anterior upper lobe, probably residual mucoid impaction and subsegmental atelectasis. Unchanged emphysematous changes.
PLEURA/PERICARDIUM: No abnormal PSMA uptake.
THORACIC NODES: Unchanged mild PSMA uptake in bilateral axillary lymph nodes, for example:
*Right axillary 1.2 x 0.9 cm, SUV 3.0 (image 117), previously 1.2 x 0.9 SUV 2.3
*Left axillary 1.3 x 0.9 cm, SUV 2.2 (image 110), previously 1.3 x 0.7 SUV 2.1
*Subcarinal (image 196) SUV 2.9, previously 2.5
HEPATOBILIARY:Multiple new non-avid hypodense hepatic lesions. For example:
*Segment 5, 2.8 x 2.2 (image 125)
*Segment 7/8, 2.7 x 2.5 cm, (image 155)
*Segment 2 (image 169) 3.2 x 2.6 cm
SPLEEN: Physiologic PSMA uptake.
PANCREAS: No abnormal PSMA uptake.
ADRENAL GLANDS: No abnormal PSMA uptake.
KIDNEYS/URETERS/BLADDER: Excreted physiologic PSMA activity is present. Redemonstrated photopenic large left renal cysts.
ABDOMINOPELVIC NODES: Unchanged non PSMA avid abdominopelvic lymph nodes, for example:
*Left common iliac 0.8 cm SUV 1.4,
*Right external iliac 0.8 cm SUV 1.8
BOWEL/PERITONEUM/MESENTERY: Physiologic PSMA uptake in the small bowel and colon. No abnormal PSMA uptake.
PROSTATE GLAND/SEMINAL VESICLES: Increased in size of heterogeneously PSMA avid irregular enlarged prostate gland with low attenuation necrotic and solid components. For example, PSMA avid left side solid component extending into left pelvic wall, 5.2 x 3.2 cm, SUV 6.1 image 42), previously 2.1 x 2.1 cm, SUV 5.6. Increased intensity of posterior border of necrotic component abutting the anterior rectal wall SUV 8.5.
Increasing left pelvic lymphocele 4.8 x 4.0 cm, previously 4.3 x 3.4 cm.
BONES/SOFT TISSUES: Unchanged PSMA avid osseous lesions, for example:
*Right iliac SUV 2.4 (image 256), previously SUV 2.4
*Right lower hemisacrum SUV 1.3 (image 271) SUV 1.2
OTHER FINDINGS: None.
IMPRESSION:
Since February 2, 2024,
1. Increased size of heterogenously PSMA avid prostate lesions abutting the rectum and left pelvic wall.
2. Multiple new non-PSMA avid hypodense hepatic lesions, indeterminant. Differentials can include metastatic prostate (dedifferentiated), new primary neoplasm, or non-malignant process. Recommend MRI liver protocol for further characterization.
3. Unchanged minimally PSMA avid bilateral axillary and abdominopelvic lymph nodes.
4. Unchanged osseous lesions.
5. Non PSMA avid new subcentimeter solid nodule and ground-glass opacity, nonspecific. Attention on follow-up imaging.
The following terms are used to convey the radiologist's level of certainty for a given interpretation.
Consistent with > 90%
Suspicious for/Probable/Probably approx 75%
Possible/Possibly approx 50%
Less likely approx 25%
Unlikely < 10%
Electronically Signed By: